Recommendation of the President – Iwilfin (eflornithine)
On 6 February 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 22/2026 on the validity of granting approval for the reimbursement of the medicinal product Iwilfin (eflornithine) for the indication: maintenance treatment of recurrent neuroblastoma in remission